FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Aims to Cut Comparative Efficacy Studies for Biosimilars

[ Price : $8.95]

FDA proposes a major shift in how biosimilars are evaluated, signaling that many products may no longer need traditional comparati...

FDA Drug Onshoring Policies Could Work: Attorneys

[ Price : $8.95]

Two Hyman, Phelps & McNamara attorneys report on the optimistic tone at a recent FDA public meeting on increasing U.S. drug manufa...

Multiple Violations Seen in Contec Medical Inspection

[ Price : $8.95]

FDA warns Chinas Contec Medical Systems about Quality System and Medical Device Reporting violations in its manufacturing of sever...

FDA Signals Pragmatic Push to Ease Biosimilar Development

[ Price : $8.95]

FDA Office of Therapeutic Biologics and Biosimilars director Sarah Yim says the agency is focused on making biosimilar development...

BioMarins sBLA for Palynziq for Expanded Use

[ Price : $8.95]

FDA accepts for priority review a BioMarin Pharmaceutical supplemental BLA for Palynziq (pegvaliase-pqpz) to expand the therapys u...

Rare Cancer Seamless Clinical Trials

[ Price : $8.95]

A Friends of Cancer Research working group white paper makes the case for seamless clinical trials for rare cancers.

Revolution Medicines Wins Orphan Drug Status

[ Price : $8.95]

FDA grants Revolution Medicines an orphan drug designation for its investigational therapy daraxonrasib for treating pancreatic ca...

Regeneron Gets Complete Response on Eylea sBLA

[ Price : $8.95]

FDA sends Regeneron a complete response letter for its pre-filled Eylea HD syringe supplemental BLA, citing unresolved inspection ...

Multiple Violations at 3 Royal Philips Facilities

[ Price : $8.95]

FDA warns Royal Philips, based in the Netherlands, about multiple violations at two of its U.S. medical device manufacturing facil...